Fairmount Funds Management LLC sold $242.6M of Cogent Biosciences (COGT)

Executed Mar 31, disclosed Mar 31, the same day.

Value, as filed

$242.6M

7,000,000 sh × $34.66

Executed

Mar 31

the trade date, as filed

Disclosed

Mar 31

0 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

FL Fairmount Funds Management LLC Director profile →

Fairmount Funds Management LLC (Director) filed 8 Form 4 reports as a reporting entity in the trailing twelve months (4 purchases, 4 sales), most often in Cogent Biosciences, Inc. (COGT). Across 4 priced purchase filings, the average 21-session return was -7.3% from execution and -3.8% from disclosure (delay-adjusted; derived). The largest single filing was $399.7M of SYRE (4,684,781 sh × $85.31, as filed), executed Jun 23.

The name

COGT

Cogent Biosciences, Inc. COGT · Healthcare · 9 filings in 24 months ticker →

Healthcare · Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Fairmount Funds Management LLC in COGT

COGTSALE Cogent Biosciences, Inc. $127.4M
3,500,000 sh × $36.40
Exec Jan 22
Filed Jan 22 · 5:30 PM ET COGTPURCHASE Cogent Biosciences, Inc. $25.0M
2,777,777 sh × $9.00
Exec Jul 10 2025
Filed Jul 14 2025 · 5:30 PM ET